LIRA, UGANDA》Uganda has taken a major step forward in HIV prevention with the official launch of Lenacapavir, a long-acting injectable pre-exposure prophylaxis (PrEP), at Lira Regional Referral Hospital.
The launch was officiated by the Minister of Health, Jane Ruth Aceng, who described the introduction of Lenacapavir as a “game-changer” in the country’s ongoing fight against HIV/AIDS.
Lenacapavir is a long-acting antiretroviral drug administered once every six months to individuals at substantial risk of acquiring HIV. Unlike daily oral PrEP, the injectable offers a more convenient option, particularly for people who struggle with adherence to daily medication.
Dr. Aceng emphasized that the drug is not a vaccine, but a preventive treatment designed for HIV-negative individuals following confirmed testing.
“This innovation will significantly strengthen our prevention efforts, especially among populations at higher risk,” she said during the ceremony.
According to the Ministry of Health, the rollout of Lenacapavir will be conducted in phases, with priority given to high HIV-burden districts and vulnerable populations, including:
Sex workers
Adolescent girls and young women
Serodiscordant couples
Key populations at increased risk
By December 2026, at least 300 health facilities across the country are expected to be offering the injectable drug, greatly expanding access beyond major urban centers.
Health officials say the introduction of Lenacapavir aligns with Uganda’s broader HIV prevention strategy, which includes testing, counseling, condom distribution, and oral PrEP programs.
Dr. Aceng noted that the government is working closely with international partners to ensure sustainable supply, training of health workers, and community sensitization to support uptake.
Leaders and health workers in Lira welcomed the launch, describing it as timely for the Lango sub-region, which continues to face HIV prevalence challenges.
Medical staff at Lira Regional Referral Hospital expressed optimism that the injectable option will improve adherence and reduce new infections, particularly among young people.
The Ministry of Health is expected to monitor uptake and effectiveness closely during the phased rollout, with plans to expand coverage nationwide if outcomes remain positive.
With Lenacapavir now introduced, Uganda joins a growing number of countries adopting long-acting HIV prevention technologies-marking a significant milestone in the push toward ending new HIV infections.
#+256770694073
#amolatarpost@gmail.com
